| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| 1 | 08-08-2025 | 06-30-2025 | 10-Q | |
| 2 | 05-06-2025 | 03-31-2025 | 10-Q | |
| 3 | 02-24-2025 | 12-31-2024 | 10-K | |
| 4 | 11-04-2024 | 09-30-2024 | 10-Q | |
| 5 | 08-06-2024 | 06-30-2024 | 10-Q |
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Piper Sandler analyst David Westenberg maintains Tempus AI (NASDAQ:TEM) with a Neutral and raises the price target from $70 ...
BTIG analyst Mark Massaro maintains Tempus AI (NASDAQ:TEM) with a Buy and raises the price target from $85 to $96.
Tempus AI (NASDAQ:TEM) shares are trading higher Monday after the company announced its subsidiary, Ambry Genetics, published a...
Study finds significantly lower rates of provider-initiated exome reanalysis among diverse racial, ethnic, and ancestral groups...
Top large-cap losers last week included IonQ, Tempus AI, AeroVironment, Astera Labs, Nebius, Kratos, F5, Klarna, Leonardo DRS, ...
Whitehawk Therapeutics announced a multi-year partnership with Tempus AI, but its stock fell 8.81% in after-hours trading follo...
Whitehawk Therapeutics shares are rising Thursday after the company announced a multi-year collaboration with Tempus AI to supp...
Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a ...
